China Shineway Pharmaceutical Group Limited
CSWYY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.04 |
| FCF Yield | 31.27% | 20.77% | 0.00% | 203.89% |
| EV / EBITDA | -53.14 | -110.30 | 0.00 | -11.50 |
| Quality | ||||
| ROIC | 0.49% | 0.36% | 0.00% | 4.34% |
| Gross Margin | 72.22% | 74.47% | 0.00% | 75.08% |
| Cash Conversion Ratio | 1.12 | 2.09 | 1.28 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.43% | 10.10% | 17.08% | 16.69% |
| Free Cash Flow Growth | 53.50% | 0.00% | 0.00% | 89.57% |
| Safety | ||||
| Net Debt / EBITDA | -55.35 | -115.39 | 0.00 | -12.05 |
| Interest Coverage | 63.23 | 84.05 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.09 | 0.07 | 0.00 | 0.59 |
| Cash Conversion Cycle | 991.69 | 1,072.88 | 0.00 | 123.98 |